Suprofen treatment of contact lens-associated giant papillary conjunctivitis.
This multicenter study of patients with contact lens-associated giant papillary conjunctivitis (GPC) was a randomized, double-masked comparison of a 1.0% suprofen solution versus the suprofen vehicle solution (placebo). Patients were given two drops of medication four times daily for up to 28 days and were clinically examined on days 0, 2, 7, 14, 21, and 28. The physicians' clinical judgments of the patients' responses to therapy significantly favored suprofen over placebo at day 21 (P = 0.02), while strongly favoring suprofen at day 14 (P = 0.057) and at day 28 (P = 0.067). The patients' opinions of their response to therapy significantly favored suprofen on day 14 (P = 0.03); a trend for suprofen was evident on day 28 (P = 0.1). Treatment with suprofen led to a greater overall reduction in ocular signs and symptoms than with placebo. Strong trends approaching statistically significant levels were found for reductions in the principal ocular sign, papillae, at day 28 (P = 0.068) and in mucus strands at days 14 and 28 (P = 0.09), which also favored suprofen.
Wood
T S
TS
Department of Ophthalmology, UTHSC-Dallas, TX.
Stewart
R H
RH
Bowman
R W
RW
McCulley
J P
JP
Reaves
T A
TA
D000328:Adult; D003233:Conjunctivitis, Allergic / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D003261:Contact Lenses / Q000009:adverse effects*; D005128:Eye Diseases / Q000139:chemically induced; D006801:Humans; D007600:Judgment; D010666:Phenylpropionates / Q000627:therapeutic use*; D010820:Physicians; D013496:Suprofen / Q000009:adverse effects / Q000627:therapeutic use*
D010666:Phenylpropionates; D013496:Suprofen